Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ELVIRA LINDWALL

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1881890713
CMS profile
221956
Location
THOUSAND OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20,290.98

185 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ELVIRA LINDWALL

NPI 1881890713 · CMS profile ID 221956

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

THOUSAND OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881890713?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ELVIRA LINDWALL, NPI 1881890713, CMS profile ID 221956. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881890713?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ELVIRA LINDWALL, NPI 1881890713, CMS profile ID 221956. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881890713?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ELVIRA LINDWALL, NPI 1881890713, CMS profile ID 221956, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 185 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1881890713?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

185 matching records · $20,290.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 185 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 185.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $22.1909/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807418375 CMS
Lilly USA, LLC $25.0209/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819079007 CMS
GlaxoSmithKline, LLC. $8.5709/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802646802 CMS
DePuy Synthes Sales Inc. $32.8509/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787500489 CMS
Novartis Pharmaceuticals Corporation $12.6709/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030855 CMS
AbbVie Inc. $8.8209/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344863 CMS
Novartis Pharmaceuticals Corporation $9.6109/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030825 CMS
Novartis Pharmaceuticals Corporation $25.7909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030835 CMS
Novartis Pharmaceuticals Corporation $5.4309/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030871 CMS
AbbVie Inc. $28.3109/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344857 CMS
AstraZeneca Pharmaceuticals LP $21.7309/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830116639 CMS
Novartis Pharmaceuticals Corporation $21.9209/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030809 CMS
Novartis Pharmaceuticals Corporation $18.2009/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030819 CMS
Novartis Pharmaceuticals Corporation $23.2809/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030829 CMS
Amgen Inc. $25.3709/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825296979 CMS
Amgen Inc. $22.1609/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825297043 CMS
Lilly USA, LLC $1,800.0009/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819129777 CMS
Lilly USA, LLC $675.0009/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819175745 CMS
PFIZER INC. $31.8509/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832835541 CMS
Lilly USA, LLC $20.9509/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819079005 CMS
Genentech USA, Inc. $21.6409/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835909447 CMS
Amgen Inc. $25.0308/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825297039 CMS
E.R. Squibb & Sons, L.L.C. $12.9508/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783580117 CMS
AbbVie Inc. $8.2608/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344851 CMS
Aurinia Pharma U.S., Inc. $108.9908/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841406129 CMS
Amgen Inc. $24.0208/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825297019 CMS
AbbVie Inc. $4.3408/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344847 CMS
Genentech USA, Inc. $15.3908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835909451 CMS
AbbVie Inc. $3.1608/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344841 CMS
Amgen Inc. $117.8508/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826332763 CMS
Lilly USA, LLC $28.5208/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819175749 CMS
AbbVie Inc. $8.0608/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344835 CMS
Novartis Pharmaceuticals Corporation $12.9208/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030793 CMS
Novartis Pharmaceuticals Corporation $12.0308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030803 CMS
Novartis Pharmaceuticals Corporation $16.8708/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030815 CMS
Novartis Pharmaceuticals Corporation $9.1608/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813030851 CMS
AbbVie Inc. $5.0508/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344829 CMS
Lilly USA, LLC $1,800.0008/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819070261 CMS
PFIZER INC. $8.5008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832871899 CMS
AbbVie Inc. $12.4308/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344823 CMS
Amgen Inc. $11.3808/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825297035 CMS
Lilly USA, LLC $32.0007/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 856541199 CMS
GlaxoSmithKline, LLC. $23.4107/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802529683 CMS
Janssen Biotech, Inc. $35.6107/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788787657 CMS
AbbVie Inc. $3.5007/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344817 CMS
Amgen Inc. $32.3407/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825297015 CMS
AbbVie Inc. $27.8307/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344811 CMS
AbbVie Inc. $4.8307/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344807 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.6907/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763658666 CMS
AbbVie Inc. $26.9907/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795344801 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,790.45 346
PY2020 $24,330.13 224
PY2021 $20,290.98 185
PY2022 $14,167.28 314
PY2023 $21,835.51 295
PY2024 $8,312.58 238
PY2025 $6,389.14 230

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $214,132.85 20
PY2024 Principal investigator $671,569.47 18
PY2023 Principal investigator $307,109.32 30
PY2022 Principal investigator $296,666.36 30
PY2021 Principal investigator $96,860.52 19
PY2020 Principal investigator $15,744.15 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $250.92 12/31/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) No dispute reported 06/30/2026 1202535099
Principal investigator 1 ABBVIE INC. $3,047.80 12/04/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527124
Principal investigator 1 ABBVIE INC. $7,026.40 11/04/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520651
Principal investigator 1 ABBVIE INC. $51.00 10/09/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202515379
Principal investigator 1 Eli Lilly and Company $20,330.00 09/29/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL (ATTAIN-OA PAIN) ; J2A-MC-GZT1 ; J2A-MC-GZT2 No dispute reported 06/30/2026 1187878957
Principal investigator 1 Eli Lilly and Company $111.45 08/21/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187877197
Principal investigator 1 ABBVIE INC. $1,000.00 08/05/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501736
Principal investigator 1 ABBVIE INC. $3,900.00 07/28/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500134
Principal investigator 1 ABBVIE INC. $2,794.30 07/02/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494423
Principal investigator 1 SANOFI US SERVICES INC. $7,842.00 07/02/2025 Non-covered Recipient Entity
Millennium Clinical Trials Llc
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226108954
Principal investigator 1 ABBVIE INC. $969.15 05/06/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481525
Principal investigator 1 ABBVIE INC. $3,800.00 04/08/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202474914
Principal investigator 1 ABBVIE INC. $7,026.40 04/03/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202470834
Principal investigator 1 Janssen Research & Development, LLC $7,712.00 03/17/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175415780
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,184.25 03/06/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy No dispute reported 06/30/2026 1190311157
Principal investigator 1 ABBVIE INC. $3,600.00 02/18/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202452232
Principal investigator 1 ABBVIE INC. $14,218.77 02/05/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202444459
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,095.64 01/15/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190311153
Principal investigator 1 Novartis Pharmaceuticals Corporation $76,258.87 01/09/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190311159
Principal investigator 1 ABBVIE INC. $2,913.90 01/02/2025 Non-covered Recipient Entity
MILLENNIUM CLINICAL TRIALS LLC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202434103